The 12 closest competitors and alternatives to Implicit Bioscience Inc among biotechnology companies — ranked by similarity to what Implicit Bioscience Inc actually does, not by market-cap band.
Subscribe to see Implicit Bioscience Inc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Implicit Bioscience, Inc. is a biotechnology company founded in 2002 that focuses on the clinical development of novel immunotherapies and treatments for critical illnesses.
Implicit Bioscience Inc is a biotechnology company headquartered in Australia. It has raised at least $818,643 across the 5 funding rounds on record. Its most recent funding round raised $65,551 in August 2020. Xcout tracks 14 named people at Implicit Bioscience Inc, including Garry Redlich (CEO & MD).
8 more named people on record for Implicit Bioscience Inc, with roles, board committees and tenure — see the full roster →
At least $818,643 raised across the 5 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $65,551 | — | |
| SEC Form D filing | $367,227 | — | |
| SEC Form D filing | $125,000 | — | |
| SEC Form D filing | $210,065 | — | |
| SEC Form D filing | $50,800 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Ranked by semantic similarity — how close each company is to Implicit Bioscience Inc by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
ImmPACT Bio USA, Inc. is a clinical-stage biotechnology company headquartered in West Hills, California. The company focuses on developing advanced cell therapies and immunotherapies to treat cancer and other serious diseases.
Similar biotechnology company
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
Biotech
Sensei Biotherapeutics, Inc. is a clinical stage biotechnology company focused on the discovery and development of new therapies.
Similar biotechnology company
Immunomic Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland, that develops innovative immune therapies.
Similar biotechnology company
Amplica Bio, Inc. is a biotechnology company that develops next-generation biologics and therapies aimed at targeting difficult diseases. The company engages in drug engineering to address challenging therapeutic targets.
Biotech
Impact BioMedical Inc. is a pioneering biotechnology company incorporated in 2018 and based in Houston, Texas, dedicated to discovering, developing, and patenting innovative healthcare products, drug pipelines, and technology platforms.
Similar biotechnology company
ImmunoPhotonics, Inc. is a privately owned clinical-stage biopharmaceutical and pharmaceutical manufacturing company located in St. Louis, Missouri, specializing in interventional immuno-oncology.
Life Sciences
Triumvira Immunologics Inc. is a privately held biopharmaceutical and biotechnology research company engaged in developing novel immunotherapies.
Similar biotechnology company
IMBiologics Corp. is a biotechnology company headquartered in Suwon-si, Gyeonggi-do, South Korea. The firm focuses on drug discovery, development of biotherapeutic pipelines, and clinical trials for innovative antibody treatments.
Similar biotechnology company
Ambros Therapeutics is a clinical-stage biotechnology company headquartered in Irvine, California, focused on the development of innovative therapeutics.
Biotech
ImmunityBio, Inc. is a public clinical-stage immunotherapy company headquartered in San Diego, California. As a member of the NantWorks ecosystem, it focuses on developing next-generation cancer vaccines and immunotherapies.
Similar biotechnology company
ImCheck Therapeutics designs and develops next-generation immunotherapeutic antibodies focused on modulating the immune system through the butyrophilin and butyrophilin-like superfamily of checkpoint molecules. The company's pipeline targets treatments for cancer, infectious disease, and autoimmune disease.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Implicit Bioscience Incand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →